TDB, Sapigen Biologix ink agreement to commercialise intranasal COVID-19, RTS, S Malaria vaccine https://ift.tt/16TYuRC

Under the agreement signed, Technology Development Board and Bharat Biotech have pledged support of Rs 200 crore each to create a continuous corpus of Rs 400 crore for development and commercialisation of two novel vaccines –‘Intranasal COVID-19 Vaccine’ and ‘RTS, S Malaria Vaccine’.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/vRinEgy
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.